Skip to main content
Trending
Enterprise aiDefense procurementFoldable phonesMaritime tradeConsole securityEpidemic responseMonetary policyAgentic commerceAgricultural biosecurityClinical trialsCorporate mergersCurrency defenseHumanoid roboticsVaccine safetyWest bank tensionsZero-day exploitationZoonotic spilloverAbortion rightsAi supply chainAutonomous agentsAutonomous vehiclesCancer immunotherapyData breachEnergy policyFighter procurementHoliday hiringHostage diplomacyIndustry layoffsParticle physicsSahel security

full timeline

Moderna mRNA cancer vaccine development

A personalized mRNA cancer vaccine combined with immunotherapy reduced the risk of melanoma returning or causing death by 42 percent in a late-stage trial. The results mirror earlier Phase 2 findings, validating a custom-built approach that trains the immune system to target specific tumor mutations.

Factlen Newsroom· Updated

Follow Moderna mRNA cancer vaccine development in the Factlen app and get an alert when there is news. Get the app

Illustration: Moderna and Merck's personalized mRNA vaccine is custom-built for each patient based on the genetic signature of their surgically removed tumor.From: Full Phase 3 Trial Confirms Moderna and Merck mRNA Vaccine Halves Melanoma Recurrence Risk

Share this story

Charts, maps and images

The vaccine delivers mRNA instructions to the patient's cells, training the immune system to recognize up to 34 specific mutated proteins.From: Full Phase 3 Trial Confirms Moderna and Merck mRNA Vaccine Halves Melanoma Recurrence Risk ·
Patients receiving the combination therapy showed a higher rate of recurrence-free survival after two years compared to those on standard immunotherapy.From: Full Phase 3 Trial Confirms Moderna and Merck mRNA Vaccine Halves Melanoma Recurrence Risk ·
Moderna shares experienced their steepest single-day decline of 2026 following the data breach.From: Moderna Plunges 25% and Sheds $24 Billion in Market Value Following Cancer Vaccine Data Leak ·
Clinical trial embargoes are designed to protect study blinding and ensure simultaneous information release.From: Moderna Plunges 25% and Sheds $24 Billion in Market Value Following Cancer Vaccine Data Leak ·
Moderna shares surged up to 9% following the announcement of the ESMO Presidential Symposium slot.From: Moderna's Personalized mRNA Cancer Vaccine Secures 'Practice-Changing' ESMO Symposium Slot ·
Illustration: The companies are preparing to file for regulatory approval, targeting a commercial launch for the personalized vaccine in 2027.From: Full Phase 3 Trial Confirms Moderna and Merck mRNA Vaccine Halves Melanoma Recurrence Risk ·
Show 2 more
Illustration: The experimental mRNA vaccine is designed to train the immune system to target specific melanoma mutations.From: Moderna Plunges 25% and Sheds $24 Billion in Market Value Following Cancer Vaccine Data Leak ·
The ESMO Presidential Symposium is typically reserved for first-time disclosures of practice-changing clinical datasets.From: Moderna's Personalized mRNA Cancer Vaccine Secures 'Practice-Changing' ESMO Symposium Slot ·

Timeline

October 2026

  1. Full Phase 3 Trial Confirms Moderna and Merck mRNA Vaccine Halves Melanoma Recurrence Risk
  2. Moderna Plunges 25% and Sheds $24 Billion in Market Value Following Cancer Vaccine Data Leak

September 2026

  1. Moderna's Personalized mRNA Cancer Vaccine Secures 'Practice-Changing' ESMO Symposium Slot